Immuneering Corporation
IMRX · Nasdaq · United States
Share price · IMRX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when IMRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Nov 2026+5.5%
- Day beforeDirector or principal officer change
- 6 Nov 2026+9.2%
- 30 Oct 2026-6.8%
- 11 Sep 2026-6.6%
- 1 Jun 2026-22.1%
- 29 May 2026+14.0%
Nothing announced by IMRX that day or the session before.
- 28 Apr 2026-9.2%
Nothing announced by IMRX that day or the session before.
- 23 Apr 2026+4.1%
Nothing announced by IMRX that day or the session before.
- 14 Apr 2026-5.1%
Nothing announced by IMRX that day or the session before.
- 8 Jan 2026-43.2%
- Day beforeOther material event
Share of unusual movement by asset
For each asset, the share of IMRX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | MEK (MAP2K1/2)Small molecule | Non-Small Cell Lung CancerPancreatic Cancer |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
June 2027 (1)
What to watch
2028 (1)
June 2028 (1)
What to watch
2029 (1)
May 2029 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $21M | $58M+ $87M short-term inv. | $24M-$17M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $14M | $41M+ $109M short-term inv. | $17M-$17M operating cash flow | report ↗ |
| 2026-Q1 | — | $11M | $47M+ $109M short-term inv. | $13M-$18M operating cash flow | report ↗ |
| 2025-Q3 | — | $11M | $228M | $15M-$12M operating cash flow | report ↗ |
| 2025-Q2 | — | $10M | $26M | $14M-$9.4M operating cash flow | report ↗ |
| 2025-Q1 | — | $11M | $36M+ $0 short-term inv. | $15M-$14M operating cash flow | report ↗ |
| 2024-Q3 | — | $11M | $45M+ $5.5M short-term inv. | $15M-$13M operating cash flow | report ↗ |
| 2024-Q2 | — | $11M | $60M+ $0 short-term inv. | $14M-$12M operating cash flow | report ↗ |
| 2024-Q1 | — | $11M | $66M+ $5.0M short-term inv. | $14M-$15M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $10M | $68M+ $29M short-term inv. | $13M-$12M operating cash flow | report ↗ |
| 2023-Q2 | $0 | $9.4M | $104M+ $5.0M short-term inv. | $12M-$11M operating cash flow | report ↗ |
| 2023-Q1 | $0 | $10M | $77M+ $14M short-term inv. | $14M-$14M operating cash flow | report ↗ |
| 2022-Q3 | <$0.1M | $9.4M | $76M+ $41M short-term inv. | $13M-$11M operating cash flow | report ↗ |
| 2022-Q2 | $0.1M | $8.0M | $88M+ $40M short-term inv. | $12M-$9.4M operating cash flow | report ↗ |
| 2022-Q1 | $0.2M | $9.1M | $75M+ $63M short-term inv. | $13M-$12M operating cash flow | report ↗ |
| 2021-Q3 | $0.5M | $6.2M | $107M+ $43M short-term inv. | $8.5M-$9.0M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $42M | $129M+ $44M short-term inv. | $14M-$45M operating cash flow | report ↗ |
For fiscal 2025, Immuneering reported no disclosed revenue, with R&D spend of $42.05M, down 12.3% YoY from $47.96M. Cash and equivalents were $128.65M, and the company reported a net loss of $56.02M, with quarterly net burn of $56.02M.
The company is focused on advancing atebimetinib, its lead Deep Cyclic Inhibitor, and is initiating the global Phase 3 MAPKeeper 301 trial in first-line pancreatic cancer, with first dosing expected in mid-2026. Interim Phase 2a data for atebimetinib combined with modified gemcitabine/nab-paclitaxel showed 64% overall survival at 12 months in the initial intent-to-treat population. Immuneering also entered clinical supply agreements with Regeneron for Libtayo and Eli Lilly for olomorasib, while pausing further internal advancement of envometinib to prioritize atebimetinib. Near-term milestones include updated survival data from the pancreatic cancer cohort and updated circulating tumor DNA data in 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $48M | $36M+ $0 short-term inv. | $15M-$55M operating cash flow | report ↗ |
| 2023-FY | $0 | $42M | $59M+ $26M short-term inv. | $13M-$49M operating cash flow | report ↗ |
| 2022-FY | $0.3M | $36M | $73M+ $33M short-term inv. | $13M-$44M operating cash flow | report ↗ |
| 2021-FY | $2.1M | $27M | $75M+ $74M short-term inv. | $8.4M-$31M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 8 purchases ($360K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-13 | Gengos Andrew · Chief Financial Officer | Open-market purchase | 25,000 | $3.58 | $90K | Form 4 |
| 2026-11-09 | Bogle Grant C. · director | Award / grant (derivative) | 66,700 | — | — | Form 4 |
| 2026-07-16 | Gengos Andrew · Chief Financial Officer | Award / grant (derivative) | 650,000 | — | — | Form 4 |
| 2026-06-23 | Zeskind Benjamin J. · director, PRESIDENT AND CEO | Open-market purchase | 2,400 | $4.56 | $11K | Form 4 |
| 2026-06-15 | Hall Brett Matthew · CHIEF SCIENTIFIC OFFICER | Open-market purchase | 6,035 | $4.15 | $25K | Form 4 |
| 2026-06-11 | Feinberg Peter · director | Award / grant (derivative) | 33,350 | — | — | Form 4 |
| 2026-06-11 | KEATING LAURIE · director | Award / grant (derivative) | 33,350 | — | — | Form 4 |
| 2026-06-11 | CARPENTER ROBERT J · director | Award / grant (derivative) | 33,350 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 94 reporting institutions held 29.2M shares ($143.2M).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 9,697,938 | $51.1M |
| 2 | Sanofi | 2,708,559 | $14.3M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2,288,341 | $12.1M |
| 4 | MARSHALL WACE, LLP | 1,996,585 | $10.5M |
| 5 | BlackRock, Inc. | 1,507,258 | $7.9M |
| 6 | MILLENNIUM MANAGEMENT LLC | 1,102,712 | $5.8M |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 637,944 | $3.4M |
| 8 | Occam Crest Management LP | 545,098 | $2.9M |
| 9 | CITADEL ADVISORS LLC | 447,278 | $2.4M |
| 10 | Connor, Clark & Lunn Investment Management Ltd. | 400,363 | $2.1M |
| 11 | Summit Financial, LLC | 376,749 | $2.0M |
| 12 | UBS Group AG | 376,284 | $2.0M |
| 13 | GOLDMAN SACHS GROUP INC | 327,655 | $1.7M |
| 14 | VANGUARD FIDUCIARY TRUST CO | 322,038 | $1.7M |
| 15 | Burkehill Global Management, LP | 300,000 | $1.6M |